TEL AVIV, Israel, April 22, 2020 /PRNewswire/ -- Therapix
Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty,
clinical-stage pharmaceutical company focusing on the development
of cannabinoid-based treatments, announced today the
appointment of Mr. Gilad
Bar-Lev as CEO of the Company, effective as of May 6, 2020. Mr. Bar-Lev will replace Dr. Ascher
Shmulewitz at his position as the interim CEO of the Company.
Dr. Shmulewitz will continue to serve as the Chairman of
the Company's Board of Directors.
Mr. Gilad Bar-Lev currently
serves as a director of the Company. Mr. Bar-Lev is an active
investor with vast experience in publicly traded securities,
leveraged buyouts and venture capital. During his career, Mr.
Bar-Lev has held various leadership positions, including as CEO of
Carnie Capital, an Israeli family office, and as Executive Vice
President of Hadas Arazim Group, the parent company of the Israeli
investment house Hadas Arazim. Mr. Bar-Lev is trained as a security
analyst and began his career working for financial institutions in
both the United States and
Israel.
"After a long and rigorous search for the right CEO, I am
delighted to have Mr. Bar-Lev lead the company. I have great
confidence with Gilad and I am sure he has the capability to lead
the company on a new and successful path," said Dr. Shmulewitz.
"As a member of the Therapix Board of Directors, I learned about
the Company's strengths and what its people are capable of
achieving," Mr. Bar-Lev said. "I'm excited about the potential
embedded in Therapix and certain that my 15 years of experience in
finance together with the vast experience of Therapix's
Chairman Dr. Shmulewitz as an entrepreneur and scientist along with
the skillful and experienced management team, will strengthen
Therapix's ability to bring value to all stakeholders. I am
confident in what we can accomplish together."
Mr. Bar-Lev holds a bachelor's of arts degree in Economics and
Finance from Saint Francis College, NY.
About Therapix Biosciences (Nasdaq: TRPX):
Therapix Biosciences Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists. Our focus is creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the company is currently engaged
in the following drug development programs based on
tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol
(CBD): THX-110 for the treatment of Tourette syndrome and for the
treatment of obstructive sleep apnea; THX-160 for the treatment of
pain; and THX-210 for the treatment of autism spectrum
disorder and epilepsy. Please visit our website for more
information at www.therapixbio.com, the content of which is
not a part of this press release.
Forward Looking Statements:
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, the Company is using forward-looking
statements when it discusses the Company's potential and its
ability to deliver value to stakeholders. Because such statements
deal with future events and are based on the Company's current
expectations, they are subject to various risks and uncertainties
and actual results, performance or achievements of the Company
could differ materially from those described in or implied by the
statements in this press release. The forward-looking statements
contained or implied in this press release are subject to other
risks and uncertainties, including those discussed under the
heading "Risk Factors" the Company's Annual Report on Form 20-F
filed with the SEC on May 15, 2019,
and in subsequent filings with the U.S. Securities and Exchange
Commission. Except as otherwise required by law, the Company
disclaims any intention or obligation to update or revise any
forward-looking statements, which speak only as of the date they
were made, whether as a result of new information, future events or
circumstances or otherwise.
Investor Contact:
IR@therapixbio.com
Tel: +972-3-6167055
info@therapixbio.com
View original
content:http://www.prnewswire.com/news-releases/therapix-biosciences-announces-appointment-of-new-ceo-301045612.html
SOURCE Therapix Biosciences Ltd.